lunes, 14 de noviembre de 2022

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial - The Lancet Rheumatology

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial - The Lancet Rheumatology

No hay comentarios:

Publicar un comentario